WHO Adds Ozempic and Mounjaro to Its List of Essential Medicines

The World Health Organization has added Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, alongside other GLP-1 drugs including Trulicity and Victoza, to its essential medicines list. This designation is poised to significantly expand global access to these high-demand medications, signaling potential for increased sales volumes and broader market penetration for both pharmaceutical companies.

Analysis

The World Health Organization's decision to add GLP-1 agonists, specifically citing Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, to its essential medicines list represents a significant structural tailwind for both pharmaceutical companies. This designation serves as a powerful endorsement that is likely to accelerate the adoption of these drugs within national health systems globally, potentially unlocking large-scale government and NGO procurement channels that were previously inaccessible. The inclusion of older drugs like Trulicity (LLY) and Victoza (NVO) further solidifies the dominance of these two companies across the entire GLP-1 therapeutic class. This regulatory validation, reflected in the strongly positive sentiment signals for both NVO and LLY, reinforces the long-term volume growth narrative by expanding the total addressable market well beyond developed nations, thereby de-risking future demand forecasts.

Key Decisions for Investors

• Investors should view this WHO designation as a material positive catalyst that reinforces the long-term growth thesis for both Eli Lilly (LLY) and Novo Nordisk (NVO), justifying a continued or increased overweight position in the GLP-1 space.
• This development solidifies the duopoly of LLY and NVO in the global market, suggesting that a strategy of holding positions in both market leaders remains prudent to capture the upside of the entire category's expansion.
• Monitor future company reports for commentary on international expansion, specifically regarding pricing strategies and procurement contracts in emerging markets, as sales volumes in these new channels may come at different margin profiles than in the US and EU.